Vital Signs: 02 October 2009 – SIP
October 1, 2009
Sigma Pharmaceuticals Limited (SIP) announced that it has completed the acquisition of an established pharmaceutical brand portfolio and manufacturing facility from Bristol-Myers Squibb. On September 7 the company said the $60 million acquisition is expected to meet Sigma’s stated NPV and investment objectives and is expected to be EPS accretive in the first full year of ownership. Sigma said as part of the acquisition it would acquire the right to manufacture, market and distribute 15 ethical pharmaceutical and healthcare brands in Australia and New Zealand, the right to export a majority of the acquired brands to New Zealand and a modern pharmaceutical manufacturing facility located in Noble Park, Victoria.
0